Show simple item record

dc.contributor.authorDugan, James P.
dc.contributor.authorFingeroth, Joyce D.
dc.contributor.authorBaiocchi, Robert A.
dc.date2022-08-11T08:09:50.000
dc.date.accessioned2022-08-23T16:45:42Z
dc.date.available2022-08-23T16:45:42Z
dc.date.issued2018-07-15
dc.date.submitted2018-09-13
dc.identifier.citation<p>Clin Cancer Res. 2018 Jul 15;24(14):3273-3281. doi: 10.1158/1078-0432.CCR-17-2685. Epub 2018 Apr 9. <a href="https://doi.org/10.1158/1078-0432.CCR-17-2685">Link to article on publisher's site</a></p>
dc.identifier.issn1078-0432 (Linking)
dc.identifier.doi10.1158/1078-0432.CCR-17-2685
dc.identifier.pmid29632007
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40733
dc.description<p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractPurpose: Primary central nervous system posttransplant lymphoproliferative disorder (PCNS-PTLD) is a complication of solid organ transplantation with a poor prognosis and typically associated with Epstein-Barr virus (EBV). We hypothesized EBV lytic-phase protein expression would allow successful treatment with antiviral therapy. Patients and Methods: Thirteen patients were treated with zidovudine (AZT), ganciclovir (GCV), dexamethasone, and rituximab in EBV(+) PCNS-PTLD. Twice-daily, intravenous AZT 1,500 mg, GCV 5 mg/kg, and dexamethasone 10 mg were given for 14 days. Weekly rituximab 375 mg/m(2) was delivered for the first 4 weeks. Twice-daily valganciclovir 450 mg and AZT 300 mg started day 15. Lytic and latent protein expression was assessed using in situ hybridization and immunohistochemistry. Immunoblot assay assessed lytic gene activation. Cells transfected with lytic kinase vectors were assessed for sensitivity to our therapy using MTS tetrazolium and flow cytometry. Results: The median time to response was 2 months. Median therapy duration was 26.5 months. Median follow-up was 52 months. The estimated 2-year overall survival (OS) was 76.9% (95% CI, 44.2%-91.9%). Overall response rate (ORR) was 92% (95% CI, 64%-100%). BXLF1/vTK and BGLF4 expression was found in the seven tumor biopsies evaluated. Lytic gene expression was induced in vitro using the four-drug regimen. Transfection with viral kinase cDNA increased cellular sensitivity to antiviral therapy. Conclusions: EBV(+) PCNS-PTLD expressed lytic kinases and therapy with AZT, GCV, rituximab and dexamethasone provided durable responses. Induction of the lytic protein expression and increased cellular sensitivity to antiviral therapy after transfection with viral kinase cDNA provides a mechanistic rationale for our approach.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=29632007&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050103/
dc.subjectPCNS
dc.subjectPTLD
dc.subjectEBV
dc.subjectAZT
dc.subjectLytic infection
dc.subjectAmino Acids, Peptides, and Proteins
dc.subjectCancer Biology
dc.subjectEnzymes and Coenzymes
dc.subjectHemic and Lymphatic Diseases
dc.subjectImmune System Diseases
dc.subjectImmunology and Infectious Disease
dc.subjectNervous System
dc.subjectNeuroscience and Neurobiology
dc.subjectNucleic Acids, Nucleotides, and Nucleosides
dc.titleComplete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone
dc.typeJournal Article
dc.source.journaltitleClinical cancer research : an official journal of the American Association for Cancer Research
dc.source.volume24
dc.source.issue14
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3539
dc.identifier.contextkey12835187
html.description.abstract<p>Purpose: Primary central nervous system posttransplant lymphoproliferative disorder (PCNS-PTLD) is a complication of solid organ transplantation with a poor prognosis and typically associated with Epstein-Barr virus (EBV). We hypothesized EBV lytic-phase protein expression would allow successful treatment with antiviral therapy.</p> <p>Patients and Methods: Thirteen patients were treated with zidovudine (AZT), ganciclovir (GCV), dexamethasone, and rituximab in EBV(+) PCNS-PTLD. Twice-daily, intravenous AZT 1,500 mg, GCV 5 mg/kg, and dexamethasone 10 mg were given for 14 days. Weekly rituximab 375 mg/m(2) was delivered for the first 4 weeks. Twice-daily valganciclovir 450 mg and AZT 300 mg started day 15. Lytic and latent protein expression was assessed using in situ hybridization and immunohistochemistry. Immunoblot assay assessed lytic gene activation. Cells transfected with lytic kinase vectors were assessed for sensitivity to our therapy using MTS tetrazolium and flow cytometry.</p> <p>Results: The median time to response was 2 months. Median therapy duration was 26.5 months. Median follow-up was 52 months. The estimated 2-year overall survival (OS) was 76.9% (95% CI, 44.2%-91.9%). Overall response rate (ORR) was 92% (95% CI, 64%-100%). BXLF1/vTK and BGLF4 expression was found in the seven tumor biopsies evaluated. Lytic gene expression was induced in vitro using the four-drug regimen. Transfection with viral kinase cDNA increased cellular sensitivity to antiviral therapy.</p> <p>Conclusions: EBV(+) PCNS-PTLD expressed lytic kinases and therapy with AZT, GCV, rituximab and dexamethasone provided durable responses. Induction of the lytic protein expression and increased cellular sensitivity to antiviral therapy after transfection with viral kinase cDNA provides a mechanistic rationale for our approach.</p>
dc.identifier.submissionpathoapubs/3539
dc.contributor.departmentDepartment of Medicine, Division of Infectious Diseases and Immunology
dc.source.pages3273-3281


This item appears in the following Collection(s)

Show simple item record